dapagliflozin
AssetSmall moleculeAlso BR3003(T), Dapagliflozin/Pioglitazone, CMG190303, DW6012
Inhibits SGLT2 (SLC5A2) to block renal glucose reabsorption.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- Indications
- 41
- Trials
- 382
- Developers
- 6
Indications
41Cardiovascular death
Approvedaccessdata.fda.gov7 Oct 2026
Chronic kidney disease
Approvedaccessdata.fda.gov7 Oct 2026
Death
Approvedaccessdata.fda.gov7 Oct 2026
38 more
- Targets and what it contains5
- Owner and partners6
- Trials382
- Evidence for its targets6
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 49 sources